N-acetylcysteine amide is a potential novel radioprotector of salivary gland function Journal Article


Authors: Ritter, A.; Hikri, E.; Li, H.; Markovsky, E.; Bachar, G.; Kurman, N.; Popovtzer, A.; Haimovitz-Friedman, A.; Mizrachi, A.
Article Title: N-acetylcysteine amide is a potential novel radioprotector of salivary gland function
Abstract: <p>Background: Radiation-induced salivary gland (SG) hypofunction is mediated via microvascular dysfunction and radical oxygen species. N-acetylcysteine amide (NACA) has shown antioxidant properties with low toxicity. We explored NACA's potential as a radioprotector of SG function. Methods: Bovine aortic endothelial cells (BAECs) were treated with NACA before irradiation with a single 10 Gy dose. Apoptosis was assessed by bis-benzimide staining and quantified via fluorescence microscopy. In vivo, NACA was administered to mice prior to a single 15 Gy head and neck irradiation. Eight weeks post-irradiation, saliva production was measured using pilocarpine stimulation; lysozyme levels were analyzed by ELISA. SGs were collected for immunohistochemistry. Results: BAEC apoptosis was substantially lower in NACA-treated cells vs. radiation-only (10% vs. 23%). In vivo, mice lost significant weight and developed severe hair loss eight weeks post-irradiation-attenuated by NACA pretreatment. Saliva production was reduced by 72% post-radiation, with a corresponding drop in lysozyme. NACA increased salivary flow by 42% and prevented lysozyme reduction. Post-radiation decline in microvessel density was also prevented by NACA. Conclusions: These outcomes suggest NACA may serve as a radioprotector of SG function in patients undergoing radiotherapy for head and neck cancer.</p>
Keywords: radiation; radiotherapy; head and neck neoplasms; irradiation; xerostomia; tumor; ceramide; mechanism; radiation-therapy; protection; induced damage; acetylcysteine; cancer; hypofunction; salivary gland diseases
Journal Title: Cancers
Volume: 17
Issue: 17
ISSN: 2072-6694
Publisher: MDPI  
Date Published: 2025-09-01
Start Page: 2902
Language: English
ACCESSION: WOS:001569644700001
DOI: 10.3390/cancers17172902
PROVIDER: wos
PMCID: PMC12428364
PUBMED: 40940999
Notes: The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PubMed record and PDF -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Hongyan   Li
    12 Li